logo-loader
viewSynairgen PLC

Synairgen excited for phase II trial results in 2020

Snapshot

  • Focused on respiratory disease
  • Two drug candidates, one developed in-house, one by a partner
  • Financially well set to progress its key asset, analyst says
lung x-ray

Quick facts: Synairgen PLC

Price: 7.75 GBX

AIM:SNG
Market: AIM
Market Cap: £8.48 m
Follow

Respiratory specialist

Synairgen plc (LON:SNG) is currently running a two-part phase II trial evaluating SNG001. This is an inhaled interferon beta drug candidate designed for people with chronic obstructive pulmonary disease (COPD) who are also suffering cold or flu infections.

It has completed the first part of its SG015 study, assessing the safety of the treatment.

Synairgen said in September that the phase II trial was progressing well, with four new sites added in 2019.

The drug is being developed to treat people with COPD that are suffering exacerbations caused by cold or flu.

The biomarker data has been taken from part-one of the study, in which patients were treated when they did not have a cold or flu infection.

Analysis of samples from the lung showed treatment with inhaled interferon beta boosted the lungs' antiviral defences.

As a result, Synairgen is now more confident of a positive result from part-two, when patients do have a confirmed respiratory virus infection.

 

LOXL2

The company’s Australian partner has completed phase I trials and toxicology on a LOXL2 inhibitor developed by Synairgen.

This now paves the way for Pharmaxis to advance discussions with potential partners for the drug, which has been developed to treat non-alcoholic liver disease (NASH) and a rare lung condition.

The company retains a 17% “carried interest” in the asset.

 

Synairgen’s BioBank

Over the years, Synairgen has accumulated an extensive bank comprised of blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma or COPD. Using this resource, the company has developed a number of advanced tissue models.

It uses these models to:

•        Discover novel drug targets

•        Identify disease-related lesions and underlying molecular mechanisms

•        Conduct proof of concept testing and validation of novel drug targets

•        Conduct screening assays for novel drug targets and lead target selection

•        Provide support for clinical trial activities

 

Financially solid

Synairgen had cash and bank deposits of £3.52mln at the end of June, compared to £5.31mln a year earlier.

At the end of August, the company received its 2018 research and development tax credit of £840,000, which provides a runway to the readout of the Phase IIa study of SNG001 in COPD patients, expected in the second quarter of the next year.

Watch the interview

 

What the boss says

“We believe IFN-beta is a highly promising, and commercially attractive, therapeutic that could alleviate symptoms, help manage exacerbations and reduce healthcare costs. We look forward to completing the trial early in 2020 with results expected in Q2,” said Richard Marsden, the chief executive officer of Synairgen.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen's phase II trial on lead COPD drug 'progressing well'

Synairgen PLC's (LON:SNG) Richard Marsden tells Proactive London's Andrew Scott  the respiratory drug discovery and development company, is well-poised to complete the phase II trial on its lead candidate. The trial is expected to complete dosing in Q1 next year with results available in...

on 30/9/19

3 min read